Purpose: This study aimed to evaluate the clinical efficacy of an innovative preparation; honey inorabase (50% in 1:1) for treating atrophic/ erosive oral lichen planus (OLP) compared with triamcinolone acetonide 0.1% ointment.
Subjects And Methods: The study involved a total of 60 patients who were randomly dividedinto three groups: Group I (honey in orabase 50%, 1:1 paste), Group II (triamcinolone acetonide 0.1% ointment), and the control group, III, (orabase paste). The primary outcome measure utilized the Visual Analogue Scale (VAS), while the secondary outcome included evaluating the clinical manifestation through an OLP reduction score assessment.
Results: Compared to Group III, Groups I and II experienced significant reductions in their VASand OLP scores. Participants in Groups I and II reported minimal to no discomfort, with Group I demonstrating the most substantial pain relief.
Conclusion: In comparison to triamcinolone acetonide 0.1% ointment and the control group,the study showed that honey in orabase 50% paste is effective in the reduction of pain and lesion size in patients with atrophic/erosive OLP. Therefore, as an alternative to utilizing the traditional triamcinolone acetonide 0.1% ointment to treat atrophic/erosive OLP, honey in orabase 50% paste may be an effective treatment option.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3290/j.qi.b6043838 | DOI Listing |
Purpose: This study aimed to evaluate the clinical efficacy of an innovative preparation; honey inorabase (50% in 1:1) for treating atrophic/ erosive oral lichen planus (OLP) compared with triamcinolone acetonide 0.1% ointment.
Subjects And Methods: The study involved a total of 60 patients who were randomly dividedinto three groups: Group I (honey in orabase 50%, 1:1 paste), Group II (triamcinolone acetonide 0.
Microsyst Nanoeng
March 2025
Guangdong Provincial Key Laboratory of Sensor Technology and Biomedical Instrument, School of Biomedical Engineering, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, PR China.
Hypertrophic scar (HS) is a plaque fibrous and indurated dermal lesion that may cause physical, psychological, and cosmetic challenges for patients. Intralesional injection of triamcinolone acetonide (TA) is commonly used in clinical practice, which cause unbearable pain and uneven drug delivery within HS tissue. Herein, we developed a paper battery powered iontophoresis-driven microneedles patch (PBIMNP) for self-management of HS.
View Article and Find Full Text PDFBackground: Trichoscopy findings can differ in the skin of color requiring a dedicated approach with adequate examination in order to ensure proper diagnosis and treatment. This case series details three cases of concurrent lichen planopilaris (LPP) and female androgenic alopecia (FAGA) in the skin of color.
Methods: Gross examination of all cases revealed mild to moderate hair density thinning of the temporal and frontal scalp.
Drug Dev Ind Pharm
March 2025
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, Mumbai, India.
Objective: In the current research work, we synthesized triamcinolone acetonide palmitate (TAP), a lipophilic prodrug of triamcinolone acetonide (TA) and formulated it into lipid nanospheres (TAP-LN) to improve pharmacokinetics and tissue distribution on intravenous administration.
Significance: Triamcinolone acetonide is a parenteral glucocorticoid used to treat several inflammatory disorders. It has a short plasma half-life (2-3 h) and its parenteral administration causes severe side effects.
J Cosmet Dermatol
March 2025
Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Background: Top surgery masculinizes the chest appearance for transgender men (TM); however, some individuals may experience hypertrophic scars (HTS) or keloids following the surgery.
Objectives: This study aimed to evaluate the efficacy of combined 595-nm pulsed dye laser (PDL) and intralesional triamcinolone acetonide injection (IL TAC) compared to IL TAC monotherapy for treating HTS and keloids.
Methods: Twenty-five TM with 35 pairs of bilateral symmetric postmastectomy HTS or keloids were randomly allocated to receive the combined PDL and IL TAC on the scar(s) on one side of the chest and IL TAC monotherapy on the contralateral scar(s) in four monthly treatment sessions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!